Amgen Expects a 2024 Sales Jump, Sets Sights on Obesity Market.

AMGEN Inc.; ANTIOBESITY agents; QUARTERLY reports; BUSINESS negotiation; OBESITY

Amgen Inc. expects its revenue to increase by up to 20% this year, thanks to its acquisition of Horizon Therapeutics Plc and its entry into the weight-loss drug market. The company predicts annual sales of $32.4 billion to $33.8 billion in 2024, which aligns with analysts' projections. Amgen aims to become a major player in the obesity drug market, currently dominated by Eli Lilly & Co. and Novo Nordisk A/S, and has two experimental weight-loss drugs in development. The company's lead obesity drug, MariTide, has shown promising results in a study, and Amgen plans to share more data from a midstage trial in the second half of 2024. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)